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This study was conducted to determine whether in-
terferon-a-2b (IFN-a-2b) can be encapsulated in li-
posomes without compromising its anti-fibrogenic 
effects on human dermal fibroblasts. Tl1e rationale 
for this approach is that systemic administration of 
IFN-a-2b by injection for treatment of dermal fibro-
sis is uncomfortable, requires a large quantity of the 
cytokine, and cannot be easily used in children. 
Liposmnes are potentially useful as vehicles for the 
topical delivery of drugs if they can be encapsulated 
without loss of biologic activity. Empty sonicated 
vesicles composed of dioleoyl-phosphatidylcholine: 
dioleoyl-phosphatidylglycerol at a molar ratio of 7:3 
were mixed with various concentrations of IFN-a-2b 
and then dried and rehydrated. An enzyme-linked 
immunosorbent assay (ELISA) was used to determine 
the efficiency of encapsulation and the stability of the 
preparation under experimental conditions. Greater 
than 80% of added IFN-a-2b became associated with 
the liposmnes and remained encapsulated for up to 
5 d at 4°C. The rate of release increased markedly at 
L iposom es are single o r multilayered vesicles composed oflipid bilayers smrounding aqueous compartments. A water-soluble therapeutic agent associated with lipo-somes may be better able to penetrate cell m embranes than in the free state. Liposome preparations have been 
used successfuLl y for treatmen t of cutaneous herpes sin1plex 
(Weine r et n/, 1989) , leading us to propose that they could also be 
used to delive r ai Jti-fibrogenic fuc tors in hypertrophic scarring 
(l-ISe) and keloids, conditions that frequently develop after surgical 
incisio n, deep trauma, or severe thennal injury. In these fibrotic 
conditio ns, the bio m echanical properties of the tissue are p erturbed 
by changes in extracellular m atrix composition and organization 
(for review , see Scott et: a/, 1994). Unfortuna tely, younger p atients 
arc m o re likely to develop l-ISe and keloid scarring than are older 
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37°C. Liposome-encapsulated IFN-a-2b (2000 units 
per ml) significantly reduced the proliferation of 
dermal fibroblasts (60 ± 8.8 vs. 100 ± 8, mean ± SEM, 
p < 0.05, n = 8) and the levels of mRNA for type I 
(41.5 ± 8. 7% vs 100 ± 18, p < 0.05, n = 4) and type III 
(68 ± 8.4% vs 100 ± 4.9%, p < 0.05, n = 3) pro-
collagen, as analyzed on northern blots. This was 
consistent with the reduction found in collagen in 
conditioned medium from treated fibroblasts. In con-
trast, treatment increased levels of mRNA for colla-
genase (241 ± 42% vs 100 ± 3.4, p < 0.05, n = 3) and 
collagenase activity (289 ± 5.8% 11s 100 ± 10.9%, p < 
0.05, n = 9) in conditioned medium. This last effect 
was probably not due to a reduction in TIMP-1 (tissue 
inhibitor of metalloproteinase-1) because levels of 
mRNA for this inhibitor were not lower in treated 
cells. The efficacy ofliposome-associated IFN-a-2b in 
vitt•o supports the concept of the topical use of this 
anti-fibrogenic agent for treatment of fibroprolifera-
tive disorders. K ey wot•ds: lryputt•opltic scar!bJU'Illcollagenl 
collagwase. J Itwest D ermatol 109:55-60, 1997 
patients (Rudolph , 1987). C urrent treatm ents for th ese condi tions 
are unsatisfactory: p ressure gan11ents mus t be wom up to 2 y to be 
effective, steroid use is limited by the risk of systemic side effects 
and is not suitable for scars covering large areas, and surgical 
revision often results in recurrence (Scott el nl, 1994). 
lntetferons (IFN) are cytok:in es with biologic activities suggest-
ing that they may be useful in con trolling fibrosis. IFN-')' is secreted 
by activated T lymphocytes, whereas IFN-a and {3 are tl1e products 
ofleukocytes and fibroblasts, respectively (Sen and Lengyel, 1992). 
!11 11itro, these cytokin es reduce the syntl1esis of co llagen and inhibit 
proliferation and chemotaxis in normal human fibroblasts (Rosen-
bloom el a/, 1984; Tsutsumi el nl, 1989; Tredget et nl, 1993; Harrop 
et nl, 1995). It was also found that IFN-a-2b decreased fibronectin 
mRNA in human l-ISe and normal dermal fibroblasts (Ghahary eta/, 
1993 b) and that JFN- a -2b but not IFN-')' al so increased collagenase 
activity (Ghah ary et nl, 1995b). 
In an i11 11i11o mod el, Czaja et nl (1987) found a reduction in th e 
expression of type I pro-collagen mll..NA after IFN-')' treatment of 
hepatic fibrosis induced by schistosorniasis infection . T IJ.is reduction 
was independen t of pro-collagen gene transcription. T his cytokin e 
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has also been used in the treatment of rhew11atoid artluitis and 
membranous glomerulonephritis with some improvement (Veys et 
a/, 1988; Jonas et al, 1991). Castilla et a/ (1991) demonstrated 
reductions in .levels of mlWAs for transforming growth £1ctor-,Bl 
and type I pro-collagen in livers of patients with chronic hepatitis 
and cirrhosis and a reduction of type III collagen pro-peptide in 
serum after IFN-a-2b administration. Intralesiona] injection of 
recombinant IFN--y or -a-2b into keloid and HSc resulted in a 
reduction in size of the scars with only mild side effects (Gran stein 
et al, 1990; Larrabee et a/, 1990). 
Although previous reports suggest that lFN-a-2b could be used 
to treat dermal fibroproliferative disorders, there are at leas t three 
practical obstacles. (i) Systemic administration is not suitable for 
children due to the requirement for frequent intradermal or intrale-
sional injections. (ii) Most adult patients experience Au-like symp-
toms (five of six), £1tigue (four of six), nausea (two of six), and low 
grade fever (one of six). 1 Finally, large quantities of IFN-a-2b are 
required. Normally, topical administration oflFN-a-2b in solution 
cannot overcome these obstacles because the free cytokine does not 
penetrate the epidermis efficiently (Weiner el al, 1989). The current 
study was therefore conducted to determine whether IFN-a-2b can 
be associated with liposomes without losing its anti-fibrogenic 
effects on dermal fibroblasts. The t·esults revea]ed that it can and, 
further, that it does so without apparent cytotoxicity. 
MATEIUALS AND METHODS 
Clinical Specimens and Cell Cultures Patients who sulfered thermal 
injury and who were treated at the University of Alberta Hospital Firefight-
ers' Burn Treatment Unit were subjects for tlus study . After informed 
consent, skin-punch bi.opsies were obtained from bum patients undergoing 
elective reconstructive surgery. Cultures of fibroblasts were established as 
previously described (Tredgct et nl, 1993; Ghahary ct nl, 1993a) . Cells at 
passages 3-7 were used for treatment of dermal fibroblasts with IFN-cx-2b 
alone, liposome-encapsulated IFN-cx-2b, a vehicle for soluble IFN-a-2b, or 
empty liposomes. Treated cell s were then used to evaluate ce Ll proliferation 
and steady-state levels of ml"tNAs for collagem1se, collagenase i11hibitor 
(TlMP-1), and type "[ and type liT collagen. Detection of 18S ribosomal 
RNA was used as a control for loading ofRNA. Conditioned medium was 
collected and used for measurement of hydmxyproline content and co lla-
genase activity. 
Establishment of an Enzyme-Linked lmmunosorbent Assay 
(ELISA) for IFN-a-2b To evaluate the concentration of encapsulated 
IFN-a-2b and the rate of its release under difFerent experimental conditions, 
we established an ELISA for fFN-a - 2b . Anti-human lFN-a -2b monoclonal 
antibodies (primary) and horseradish peroxidase-conjugated goat aJlti-
human IFN-a-2b antibodies (secondary) were obtained from Dr. Pedro L. 
Saura (Cente r De Jngenieria Genetica, Y Biotechnologia, Havana, Cuba) . 
ELISA plates were coated with 2 J.Lg of primary antibody per ml in coating 
bulfer (0.1 M sodium carbonate, pH 9.6) at 4°C for 16 h. The plates were 
then washed twice with waslung bulfer (0.02 M phosphate-bulfered sa line , 
0.02'Yo Tween 20, pH 7.4). One hundred microliters of experimental sample 
containing JFN-a-2b were added to each well . fn another set of wells in the 
same plate, various concentrations of pure LFN-a-2b were added for 
standard curve determi11ation. The plates were incubated at room temper-
ature for 1. h a11d washed three times with washing buller. The conjugated 
secondary antibody at ;1 final di lu tion of 1:2000 was then added, and the 
plates were incubated at room temperature for 1 h. After washing five times 
to remove unbound antibodies, the plates were incubated with substrate 
solution (5.5 mg of a-phenylenediamine per ml , 5.5 J.Ll of H 20 2 per ml in 
phospbate-bulfered sa line) at room temperature for 30 min. T he reaction 
was then stopped by addition of 50 J.LI of 21% (wt/vol) H 2S04 , and the 
optical density was read at 490 nm with a Thermomax microplate reader 
(Molecular Devices, Menlo Park, CA). 
Preparation of Liposomes and Encapsulation of IFN-a-2b 1FN-
a -2b was encapsulated in liposomes by the dehydrated-rehydrated vesicle 
method (Eppstein and Stewart, 1981 ). Solutions of dioleoyl-phosphatidyl-
1 T redget EE, Ghahary A, Shankowsky HA, Shen YJ , N edelec B, 
Illmayer S, Dodd C , Scott J>G: Role of systemic interferon a - 2b in 
hypertrophic scarring following major thermal injury. Joiut 1ucec iug of th e 
E uropcnu Tissue Rcpnir mul Wouud H cnli11g Society, Amsterdam, Netherlands, 
August 1993. 
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choline (5.5 mg) and L-cx-phosphatidyi-DL-dioleoylglycerol (2.4 mg) in 
chloroform were mixed thoroughly in a 100-ml round bottom Bask. The 
chlorofonn \Vas then ren1oved wjth a rotary evaporator under vacuurn . The 
film of lipid formed on the wall of the fla sk was then hydrated with 300 J.Ll 
of phosphate-bulfered saline containing 1 X 1 OG units ofiFN-a- 2b per ml at 
30°C. After vortex mix ing for 3 min , 2 .7 ml of0.2 M glycine bu1fcr (pH 3.5) 
was added and the mixture was vortex mixed for another 3 min. The 
solution was then subjected to three cycles of freezi11g and thawing. The 
li posomes were subsequently co llected by centrifugation at 125 ,000 X g for 
30 min, resuspended in Du lbecco's modified Eagle's medium (DMEM) and 
sterilized by irradiation at 6000 rads. The suspension was kept at 4°C for up 
to 3 d before use . The encapsulation efficiency was calculated by dividing 
the amount of JFN-a-2 b in the pellet by the amount oflFN-a-2b added. To 
demonstrate the leakage stability , a pool ofliposomes containing fFN -a - 2b 
was divided into 18 equal portions: 9 of these were kept at 37°C and 9 were 
kept at 4°C. ·Each da y, supernatants were collected and the amount of 
IFN-a -2b released was evaluated by ELISA. 
Effects of Liposome-Encapsulated IFN-a-2b on Cell Proliferation 
Dcrn1al fibroblasts were grown in si..x-well tissue culture plates in DMEM 
containing 10% fetal bovine serum. When cells reached 70- 80'% conflu-
ency, empty liposomes (5 mg per ml) or IFN-cx-2b-containing liposomes 
(2000 units in 5 mg ofliposome per rnl) were added to triplica te wells of the 
plates. In another set of wells, 2000 units of IFN-cx-2 b in solution was added 
as a positive control. The plates were incubated for either 72 or 96 h. The 
cells were then harvested and cotmted by Coulter counter. 
Hydroxyproline Analysis by Gas Chromatography/Mass Spectrom-
etry HydrO."-}'proline in conditioned medium was determined as previ-
ously described (Tredget et nl , 1990). Briefly, the medium was dried in a 
rotary evaporator after adding a known amount ofhydro"-)'pipecolic acid as 
;m internal standard. Samples were hydrolyzed in 0.5 ml of 6 N HCI at 
ll6°C for 16 h. The N,O-triflnoroacetyl N-metl1yl ester derivative of 
hydroxyproline was prepared after drying tbe hydrolysate. Gas chromatog-
raphy/mass spectrometry analysis was performed on an HP 5890 gas 
chromatograph linked to a HP 5970 mass selective detector m01utoring the 
ions mlz 164 and 278 . Each sample was run in triplicate and the results 
expressed as picograms of hydroxyproline per mil.liliter of medium per 48 h 
obtained by re terence to a standard curve of collagen analyzed under 
identi cal conditions. 
Extraction of Cellular RNA and Northern Blot Analysis After 
treatment, culture medium was removed and cell layers were lysed in 6 ml 
of guanidinium tluocyanate as p~:ev i ously described (Ghahary ct nl , 1993b) . 
Tota l RNA was extracted by the guanidinium isothiocyanate/CsCI proce-
dure ofChirgwin et nl (1979), separated by electrophoresis, and blotted onto 
nitrocellulose filters. Fi lters were then baked Lmder vacuum for 2 h at 80°C 
and pre-hybridized in a pre-hybridization solu tion fo r 4-6 h at 42°C, as 
described (Tredget et nl, 1993). Hybridization was performed in the same 
solution at 42 °C for 16-20 h with eDNA probes for human coll :1genase, 
TlMP-1, 18S ribosomal l"tNA, or pro-al(!) or pro-al (lll) collagen . The 
eDNA probes for collagenase and 18S ribosomal l"tNA were obtained liom 
American Type Culture Collection (Rockville, MD). The eDNA probes for 
pro-collagen were kindly provided by Drs. G. Tromp, H. Kuivaniemi, and 
L. Ala-Kokko Qefferson Institute of Molecular Medicine, Philadelphia , PA). 
The eDNA probe for T IMP-1 was a gift from Dr. Dylan R . Edwards 
(University of Calgary, C algary, AD, Canada). The probes were labeled 
with [a-32P)dCTP (DuPont Canada, Mississauga, ON, Canada) by nick-
translation. Filters were initially washed at room temperature with 2X 
standard saline citrate and 0.1% sodium dodecyl sulf..1te (SDS) for 30 min , 
then for 20 min at 65 °C in O.l X standard saline citrate and O.l'X. SDS 
solution. Autoradiography was performed by exposing Kodak X-Omat film 
to the nitrocellulose filters at - 70°C in the presen ce of an enhancing screen. 
Collagenase Activity Assay This assay was carried out as described 
(Ghahary cl nl, 1996), with slight modifications. A total of three strains of 
fibroblasts, each in tripli ca te , were used for the experiment. Briefly, proteins 
in conditioned medium, derived from treated and untreated ce lls, were 
precipitated by ammotuum sulfate . The scdimented precipitates after cen-
trifugation were disso lved in assay bulfer (0 .05 M Tris(hydtO"-J'ITiethyl)ami-
nomethane, 0.2 M NaCI, 0.005 M CaCI2 , 0.02')1,, sodium azide, pH 7.4) and 
then dialyzed overnight against 4 li ters of the same bulfer. The final vo lume 
of each sample was adjusted according to the ceJI numbers determined at the 
end of each treatment. Pro-collagenase was activated proteolytically with 
trypsin and soybean trypsin inhibitor was used to inactivate the trypsin. 
Acetic acid-solub le collagen (50 J.Lg in 25 J.Ll} from bovine skin was 
incubated with the activated enzyme solution (15 J.LI per sample) in the 
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Figure 1. Release ofiFN-a-2b from liposomes is temperature- and 
time-dependent. IFN-a -2b-associa ted liposomes were incubated at 4°C 
or 37°C and the lFN-a -2b remaining was quantified by ELISA. E ITor bars, 
SEM (n = 4). 
presence of 6 M glucose for 15-24 h. T he products were then separated by 
electrophoresis on a S'X• polyacrylamide gel containing SDS. The gel was 
stained with Coomassie blue and the {31,1(3/4) and {31,2(3/4) products 
were quantified with a computerized scanner (Color OneScanner, Apple, 
Cupertino, CA) and imaging program (NIH Image Program, Bethesda, 
MD) . 
Statistical Analysis The differences in cell proliferation, hydroxypro line 
production, abw1dance of mRNA for type I and type !11 pro-collagen, 
density of {31,1(3 /4) and {31 ,2 (3/4) collagenase digestive products were 
calculated for treated cells and compared with those of controls with a 
Student's t test. p values < 0.05 were considered significant. 
RE SULTS 
Encapsulated IFN- a-2b in Liposomes Is Stable up to 5 d at 
4°C Because an ELISA kit for evaJuation o f IFN-a-2b is not 
commercially available, a double-an tibody sandwich ELISA fo r 
human IFN- a-2b was established with recombinant JFN-a - 2b as a 
standard. This assay was based on the ELISA used to quantify 
human IFN-y as reporte d by Andersson eta/ (1 989) . To ensure the 
specificity, a monoclonal antibody was used against human IFN-
a - 2b as the primary antibody to coat the plates. To increase the 
sensitivity, a horse radish peroxidase- conjugated goat anti-human 
IFN-a -2b polyclonal antibody was used as the secondary antibody . 
The sensitivity of the assay for IFN-a-2b was 100 units per ml. 
There was no cross-reaction with recombinant human IFN - ')' at a 
con centration of 500 units per ml. 
The deh ydt·ated-rehydrated vesicles of dioleoyl-phosphatidyl-
choline:L-a- phosphatidyl-DL-dioleoylglycerol used herein en cap-
sulated about 80% of the added JFN-a -2b. As shown in Fig 1 , tlli s 
association was stable at 4 °C for up to 5 d . At body temperature 
(37°C), however, release of IFN-a -2b into the liposomal superna-
tant was observed within 24 h o f incubation. 
Liposome-Encapsulated IFN-a-2b Reduces Proliferation of 
Dermal Fibroblasts To demonstrate the effects of liposome-
en capsula ted IFN- a -2b on cell viability and proliferation, cells 
Were trea ted with vehicle, IFN-a-2b alone, empty liposomes, or 
liposome-en capsulated IFN-a - 2b , and cell viability and prolifera-
tion were evaJuate d 72 and 96 h later. T hese experiments showed 
that none of these treatments had any effect on ceU viability as 
judged by exclusion of trypan blue dye. As shown in Fig 2 , either 
IFN-a -2b alone or liposome- en capsulated IFN-a- 2b significantly 
reduced cell proliferation (60 :± 8 .8 11S 100 :± 8, p < 0.05, n = 8) 
compared to th e vellicle or empty liposom es. T h e rate of pro lifer-
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Figure 2. IFN-a-2b from liposomes reduces the proliferation of 
dermal fibroblasts. Human dermal fibroblasts were treated in duplicate 
with buffer (0), IFN-a -2b alone (.). liposome alone (01 ), or liposome-
encapsulated IFN-a -2b (&ii). Cells were then harvested and counted 72 or 
96 b after treatment. En or bars, SEM (n = 4). *p < 0.05, relative to controls. 
ation of cells treated with empty liposomes was nearly the same as 
the controls. 
Liposome-Encapsulated IFN-a-2b Reduces mRNA for Pro-
collagen but Increases n1.RNA for Collagenase Levels of 
mRNA for collagenase, TIMP-1, and typ e I and type III collagen 
were evaJuated in treated and w1treated dermal fibroblasts by using 
northern blot al.l alysis . In Fig 3 , we show that IFN-a-2b aJone and 
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Figure 3. IFN-a-2b from liposomes suppresses the expression of 
type I procollagen mRNA in dermal fibroblasts. Hum:m dem1al 
ftbroblasts were treated with buffer (C), lFN-a-2b alone (IFN) , liposomes 
alone (UP), or liposome-encapsula ted IFN- a -2b (LIP + IFN) for 72 h. Total 
RNA was extracted, electrophoresed on an agarose gel, blotted onto 
n.i trocellulose, and hybridized with a eDNA for pro-al(l). (A- C) The 5.8-
and 4.8-kb transcripts detected in tlu·ee different cell strains. (D) The 18S 
ribosomal RNA used as a control for RNA loading obtained by rehybrid-
ization of tl1e blot shown in A. 
58 GH AHA I1.. Y ET AL 
A B 
150 ~ 15<1 " ~;:J 
eo 120 
u 
120 ~~ ! 
:l8 90 ~ 5!! ~ 
uz z 
oo 60 ::; t::n ;1 ~~ 30 ~ ~1;1 0 
" 0 ,..
:c 
I.FN UP Lll'+IFN CONTROL IFN LIP I.II'+IFN 
T UEA1"M CNT T lti!ATMENT 
Figure 4. Suppression of hydroxyproline synthesis by cultured 
dermal fibroblasts correlates with reduced levels of mRNAs for 
type I and type III pro-collagens. Autoradiograms corresponding to 
four blots prepared from different experim ents were hybridized with eDNA 
probes for pro-a l (I) (A . • J or pro-al (Ill) (A, D) and qua11titated by 
densitometry. T he relative expression of the mi~As was calculated 
iJ1dividuaUy fo r each lane and the values are expressed as a percentage of the 
untreated controls. (B) Hydroxyproline in culture medium from cells 
treated with vehicle (control), IFN-a-2b alone (IFN), liposomcs alone 
(LIP) , or both (IFN + UP) . Condition ed medium was amdyzcd as described 
in Mn tcrin ls n~~d M ethods. Error bnrs, SEM (n = 3-6) . *p < 0.05, relative to 
un treated controls. 
liposome-encapsulated LFN-a- 2b reduced mRNA f01· the pro-al (I) 
chain of type I collagen . When the correspondiJJg autoradiograms 
were quantifi ed by densitometry, this redu ction wa s confirmed to 
be signifi cant (41 .5 ± 8.7% 11.< I 00 ± 18, p < 0.05, n = 4) (Fig 4A, 
solid bars). Both forms of lFN-a-2b also redu ced the levels of 
mRNA for the pro-al (III) chain of type Hl co llagen (Fig 4A , o pe n 
bars). This redu ction , however, was Jess pronounced (68 ± 8.4'!/o IJS 
100 ± 4.9'X,, p < 0.05, n = 3) than that for pro-a l (1). T hese 
findings were consistent with the levels of hydrO>..')'prolinc found in 
conditio ned m edium from the treated cells. As shown in Fig 4B, 
the amount of hydroxyproline was signifi cantly lower (70.8 ± 5% 
vs 100 :!: 4.9%, p < 0.05 , n = 4) in m edium fi·om cells treated with 
fi·ee IFN-a-2b and liposome-encapsulated IFN-a-2b than in th e 
control. In contrast to the inhibi tory effect of !FN-a-2b on collagen 
production, as shown in Fig 5, both forms of IFN-a -2b in creased 
th e levels of mRNA for coll agenase. Quantitative analysis showed 
that the increase in collagenase mRNA in cell s treated w ith 
liposom e-encapsulated IFN-a-2b was significant (24 1 ± 42% 11s 
100 ± 3.4, p < 0.05, n = 3) (Fig 5B). Whe n th e blots w ere 
re bybridi zed with a eDNA specific for 18S ribosomal RNA, equa l 
loading was found (Fig SA). 
Liposomc-EncapsuJatcd IFN-a-2b Increases Collagenase 
Activity To examin e whether the in crease in mRNA for colla-
genase results in increased enzym e activity, so luble collagen was 
in cubated with ammonium sulfate-precipitated protein from un-
condition ed m edium (DM.EM) or conditioned medium obtained 
from treated and u.ntreated cell s. As shown in Fig 6A, collagenase 
present in the conditioned m edium but not in DM.EM (control) 
specifi call y digested the al (l) and a2 (1) chain s of type I collagen 
and their dim ers (tJl,1 and tJ1.,2) into 3/4 and 1 /4 fragm ents. When 
the stainj11g intensities of the col.lagen fragments w ere qua ntified by 
densitometry, the abundance of the tJl ,1(3/4) and t31 ,2(3/4) 
pmducts o f collagenase digestion was signi.ficantly greater (289 ± 
5.8% JJS 100 ± l 0.9%, p < 0 .05, n = 9) i.n conditioned m edium due 
to e ith er IFN-a-2b or liposome-encapsulated lFN-a -2b-treated 
cells re lative to the sta ining intensities fi:om the control cell s (Fig 
6B) . T he hjg her activity of co llagenase seems to be primaril y due to 
an increase in mRNA for the enzyme because the expression of 
mRNA fo r TTMP-1 was not signjfic.mtly affected (Fig 5). 
DISC U SSION 
More than 80% of the IFN-a - 2b added could be enca psulated in 
dio leoyl-phosphatidylclwlinc :L-a-phosphatidyi-D.L-d iol eoylglyc-
ero l liposomes, as assessed with the IFN-a - 2b ELISA. When kept 
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at 4°C , the loss oflFN-a -2b was negligibl e for 4 - 5 d , indica tin g th e 
feasibility of preparing )jposom e-encapsulated IFN-a-2b in advance 
for usc either experimenta ll y or clinically. T he release of about 50% 
of the lFN-a -2b within 24 h at 37°C suggests that it shou ld also be 
re leased when applied topica ll y. Furthermore, it has been reported 
that liposome encapsulation prolongs the half-life of thi s protein 
relative to free cytokine unde r the same conditi.ons (Eppstein and 
Stewart , 1982). 
Proliferation of dermal fibroblasts is an essential component of 
normal wound-healing but, if umegulated o r unduly prolonged , 
contributes to the development of fibrop roliferative disorders 
(Scott el nl , 1994). T his might be preventable if a signal to switch off 
cell proUferation could be de li vered at an appropriate time. Jn the 
current report, we have demonstrated that liposome-encapsulated 
lFN-a -2b can signifi cantly reduce ceU prolifemtion and, further-
more, that the liposomes themselves are not cytotoxic to dermal 
fibroblasts. 
T he excessive accumulation of collagen in HSc m ay be a 
manjfestation ofincr·eased synthesis and / or reduced degradation by 
metalloproteinases (Scott el nl, 1994). In our previous report, 
evidence was prese nted that conditioned m edium obtained fi·om 
HSc fibroblasts had mu ch less co llagenase activity than conditioned 
m edium from no rmal cells (Ghahary et nl, 1996). This suggests that 
the inabili ty of HSc fibroblasts to degrade type l coll agen may 
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Figure 5. IFN-a-2b from liposomcs increases mRNA for collage-
nase but not for TlMP-1. Cells were treated with buffer (control), 
IFN-a-2b alone (IFN), liposomcs alolle (UP), or liposome-encapsulated 
IFN-a -2b {LIP+ JFN) for 72 h. Total RNA was extracted, electrophoresed, 
blot-ted onto nitrocellulose, and hybridized with a eD NA probe specific for 
collagenase and subsequently with a cDN A probe for TIM P-1 (A). Blots 
were then stripped aJld rchybridized with eDNA specific fo r 18S ribosomal 
RNA as a control for loading. S 1 (cell strain 1) and S2 (ce ll strain 2) 
represent different cell strains used for tlus experiment. Autoradiograms 
corresponding to four blots prepared from different experiments were 
quantitated by densitometry and levels of m RNA for collagenase, relative to 
l SS ribosomal RNA, arc shown (B). Error har.<, SEM (n = 4). *p < 0.05 , 
relative to untreated controls. 
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Figure 6. IFN-a-2b from liposomes increased the activity of collagenase in conditioned medium. (A) Coomassie blue-stained gel of type l 
collagen fiom bovine skin after incubation with conditioned medium obtained fro m cells treated with butfer (Control), IFN-a- 2b alone (IFN-a-2b) , 
liposomes alone (Liposome), o r liposome-encapsulated IFN-a-2b (Lipo + IFN-a-2b) for 15-24 h. T he amount of protein used for the incubations was 
adjusted according to the cell numbers. Digests were electrophoresed on SDS-polyacrylamide gels (5% gels) in triplicate . T he same amow1t of type I collagen 
Was incubated with DMEM containing 2% bovine serum albumin and electrophoresed in parallel as a negative control (Collagen). Arrows indicate a l(I) and 
a2(l) chains and the dimers {31, 1 and {31 ,2. Note the appearance of the proteolysis 3/4 fragments in some lanes. (B) R esults of qum1tifying the {31 ,1 and {31,2 
3/4 fragments by densitometry, in triplica te. Etwr bars, SEM (n == 3). *p < 0.05, relative to controls. 
contribute, at least in part, to the accumulation of collagen in this 
fibrotic condition . Transforming growth fuctor-{31 has been shown 
to down-regulate collagenase and up-regulate the inhibitor 
TIMP-1 (Edwards eta/, 1987), and insulin-like growth factor-1 has 
also been shown to decrease collagenase production by dermal 
fibroblasts (Ghahary et a/, 1996). Both cytokines, therefore, m ay 
function as fibrogenic factors in HSc. Both the excessive collagen 
synthesis and the defect in collagenase production by HSc fibro-
blasts can be reversed by free or encapsulated IFN-a-2b. T he 
enhanced collagenase activity seems to be due to an increase in 
coll agenase mRNA rather than depression of collagenase inhibitor, 
because the level ofTIMP-1 mRNA was not affected. Interferon-')' 
may not have this effect because it suppresses collagenase mRNA in 
both HSc and nonnal fibroblasts (Ghahary et al, 1995b). On these 
grounds, it is suggested that IFN-a-2b may be the more appropriate 
treatment. 
A preliminary study h as demonstrated that tlus preparation can 
significantly reduce wound contraction in guinea pigs (data not 
shown) . An in 11i11o study is currently in progress to test tl-1e ability 
ofiFN-a-2b released from liposomes to diffuse into tl~e dernus after 
wounding and once there to reduce cellularity and accumulation of 
extracellular matrLX. 
T he purpose of using a liposom e preparation is to improve the 
delivery of a given biologic agent to the tissue of interest without 
compromising its activities. As shown here, the effectiven ess of 
lFN-a-2b was retained in the liposome pmparation and essentially 
identical to that ofiFN-a-2b alone. Although the diffusibility of the 
liposome preparations through the epidermis has not been investi-
gated in this study, liposomes have been shown to be effective 
vehicles for the topical delivery to skin of several drugs, including 
triamcino lone (Mezei and Gulasekharam, 1980), cortiso l (Lasch 
and Wohlrab, 1986), and econazole (Pevaryl, C ilag-Chemie, 
Schaffhausen, Switzerland). It has also been reported that adminis'-
tration of liposom e-encapsulated IFN-a-2b is more effective than 
the free cytokine in the treatment of cutaneous herpes sin~plex 
lesions in a guinea pig model (Weiner et at, 1989). T lus finding 
further supports the concept of using such a preparation as a 
therapeutic agent for tt·eatment of dermal fibroproliferative disor-
ders. Ultimately, pati.ents may benef1t from the topical application 
of liposome-encapsulated IFN-a-2b. 
This study was suppotted by the C/,i/dre/1 Hen/tit Fo1111dati01t of N01the111 A lbe11a 
(A . Glw!tm)' n11d E.E. T redget) a11d by the Toro11to Hospital for Sick C hildre11 
Fou 11dntio11 , the Finifighters' Bum Tmst of tl1e U11i11ers ity of A lbe1ta, a11d Medical 
Research Co u11cil of Cauada (A. Ghallfl l)', E.E. Tredget, a11d P.G. Scott). T he 
IFN-a-2b 11 sed ill this st11dy wns th egwerous gift of Scheli11g Cn11adn, Poi we Claire, 
Quebec, Cmwda. 
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